Key result
SGLT2 inhibitors and sacubitril-valsartan are reviewed for their potential to revolutionize the treatment of heart failure with mildly reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
This review discusses how recent trial results for SGLT2 inhibitors and sacubitril-valsartan may change the management of heart failure with mildly reduced ejection fraction.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miguel Morita Fernandes-Silva (2022) conducted a review in Heart failure with mildly reduced ejection fraction. SGLT2 Inhibitors and Sacubitril-Valsartan was evaluated. SGLT2 inhibitors and sacubitril-valsartan are reviewed for their potential to revolutionize the treatment of heart failure with mildly reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: